Not medical advice. Cerebrolysin is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Cerebrolysin is a standardised porcine brain-derived peptide preparation approved in over 45 countries for ischemic stroke, TBI, and dementia - a mixture of low molecular weight neuropeptides that functionally mimic BDNF, NGF, GDNF, and CNTF signalling.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Cerebrolysin is a standardized porcine brain-derived peptide complex containing low-MW neuropeptides (<10 kDa) that mimic endogenous neurotrophic factors.
Peer-reviewed literature typically discusses Cerebrolysin in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Cognitive-related peptides are explored for stress-response pathways, neuronal signalling, and behaviour in animal models -not as treatments for human brain conditions.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: 2–8 °C. Do not freeze. Protect from light. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 5–30 mL IV infusion or IM injection (215.2 mg/mL concentrate) · Once daily for 10–20 consecutive days per treatment cycle · IV infusion preferred for doses >5 mL; IM injection suitable for doses ≤5 mL; slow IV push for doses ≤10 mL. Peptides distribute preferentially to brain tissue and persist for up to 8 hours following IV administration. Composition (per mL): 215.2 mg porcine brain-derived peptide preparation in aqueous solution. Contraindicated in severe renal impairment and status epilepticus. Clinical trial doses in stroke: 30–50 mL daily for 10–21 days.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Cerebrolysin (FPF-1070) is a standardised low-molecular-weight fraction of polypeptides produced by enzymatic hydrolysis of purified porcine brain proteins - roughly 85% free amino acids plus a smaller bioactive peptide fraction, standardised to 215.2 mg/mL. The peptide fraction is what carries neurotrophic activity mimicking endogenous factors like BDNF, NGF and GDNF. It is supplied for laboratory research only.
It is a standardised mixture - a defined enzymatic hydrolysate of porcine brain tissue dominated by free amino acids with a low-molecular-weight (<10 kDa) bioactive peptide fraction. The ratios are manufactured to pharmaceutical specifications, so batch-to-batch variability is controlled, even though the product is not a single molecule.
Cerebrolysin is not FDA-approved in the United States and is sold here strictly as a research compound, not for human use. It is approved and marketed as a medicine in a number of other countries (for example Austria, Germany, China, Russia and South Korea) for indications including stroke, traumatic brain injury and dementia. Legal status varies by jurisdiction.
The evidence is genuinely mixed, which is worth stating plainly. A 2018 meta-analysis of nine RCTs (N=1,879) reported early reduction of neurological deficit versus placebo, while the more conservative 2023 Cochrane review found moderate-certainty evidence of probably little-to-no difference in all-cause death in acute ischaemic stroke. Alzheimer's trials report cognitive improvements, including combination studies with donepezil. These are research findings, not a treatment claim.
Small recombinant growth factors like BDNF are difficult to deliver to the brain because of their size and blood-brain-barrier exclusion, and they have very short half-lives in circulation. Cerebrolysin's peptide fraction is small enough to act centrally and collectively mimics the activity of several neurotrophic factors, which is why it is used as a tool compound for neurotrophic-signalling research.
It is a ready-to-use aqueous concentrate (215.2 mg/mL) given by IV infusion for larger volumes or IM injection for smaller ones; published stroke protocols describe pulse schedules such as 30 mL daily for around 10 days. Reported side effects are generally mild (transient dizziness, agitation), with clinical contraindications noted in status epilepticus and severe renal impairment. We describe these descriptively from the literature and make no dosing recommendation.
Cerebrolysin is supplied as an aqueous solution rather than a lyophilised powder. Store at 2-8 °C in a refrigerator - do not freeze, as freezing can cause precipitation of the peptide fraction. Protect from light. Once opened, use within the product's specified stability window.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Primary literature and registries for Cerebrolysin, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Cerebrolysin, FPF-1070, Porcine Brain-Derived Peptide Preparation, Brain-Derived Neurotrophic Peptide Complex, CERE, Renacenz